Compared to conventional protein glycosylation biomarkers (e.g., serum prostate-specific antigen, CA15, carcinoembryonic antigen [3]), which are not specific for neoplasia, circulating tumor DNA (ctDNA) can achieve greater sensitivity and specificity when used to detect cancer. The gene discussed is CEACAM5; the disease is neoplasm.